Cargando…
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15–20% of patients alive at 5 years after concomitant chemo–radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in un...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831969/ https://www.ncbi.nlm.nih.gov/pubmed/31686616 http://dx.doi.org/10.1177/1753466619885530 |
_version_ | 1783466087796441088 |
---|---|
author | Botticella, Angela Mezquita, Laura Le Pechoux, Cecile Planchard, David |
author_facet | Botticella, Angela Mezquita, Laura Le Pechoux, Cecile Planchard, David |
author_sort | Botticella, Angela |
collection | PubMed |
description | Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15–20% of patients alive at 5 years after concomitant chemo–radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in understanding of the immune profile of NSCLC has led to the development of immunotherapeutic strategies, including inhibitory molecules responsible for abrogating an anticancer immune response such as programmed cell-death 1 and programmed cell-death ligand 1. A recently published phase III trial (PACIFIC) showed for the first time an improved overall survival in stage III NSCLC patients with consolidative durvalumab. The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in stage III NSCLC, with a brief overview on future perspectives in this setting. |
format | Online Article Text |
id | pubmed-6831969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-68319692019-11-13 Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience Botticella, Angela Mezquita, Laura Le Pechoux, Cecile Planchard, David Ther Adv Respir Dis Review Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15–20% of patients alive at 5 years after concomitant chemo–radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in understanding of the immune profile of NSCLC has led to the development of immunotherapeutic strategies, including inhibitory molecules responsible for abrogating an anticancer immune response such as programmed cell-death 1 and programmed cell-death ligand 1. A recently published phase III trial (PACIFIC) showed for the first time an improved overall survival in stage III NSCLC patients with consolidative durvalumab. The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in stage III NSCLC, with a brief overview on future perspectives in this setting. SAGE Publications 2019-11-05 /pmc/articles/PMC6831969/ /pubmed/31686616 http://dx.doi.org/10.1177/1753466619885530 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Botticella, Angela Mezquita, Laura Le Pechoux, Cecile Planchard, David Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience |
title | Durvalumab for stage III non-small-cell lung cancer patients:
clinical evidence and real-world experience |
title_full | Durvalumab for stage III non-small-cell lung cancer patients:
clinical evidence and real-world experience |
title_fullStr | Durvalumab for stage III non-small-cell lung cancer patients:
clinical evidence and real-world experience |
title_full_unstemmed | Durvalumab for stage III non-small-cell lung cancer patients:
clinical evidence and real-world experience |
title_short | Durvalumab for stage III non-small-cell lung cancer patients:
clinical evidence and real-world experience |
title_sort | durvalumab for stage iii non-small-cell lung cancer patients:
clinical evidence and real-world experience |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831969/ https://www.ncbi.nlm.nih.gov/pubmed/31686616 http://dx.doi.org/10.1177/1753466619885530 |
work_keys_str_mv | AT botticellaangela durvalumabforstageiiinonsmallcelllungcancerpatientsclinicalevidenceandrealworldexperience AT mezquitalaura durvalumabforstageiiinonsmallcelllungcancerpatientsclinicalevidenceandrealworldexperience AT lepechouxcecile durvalumabforstageiiinonsmallcelllungcancerpatientsclinicalevidenceandrealworldexperience AT plancharddavid durvalumabforstageiiinonsmallcelllungcancerpatientsclinicalevidenceandrealworldexperience |